Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia

Addiction Biology

Volumn 20, Issue 2, 2015, Pages 275-284

  Park, Paula E ^a,b   Schlosburg, Joel E ^a   Vendruscolo, Leandro F ^a   Schulteis, Gery ^c,d   Edwards, Scott ^a,e   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d University of California   (United States)

^e LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute dependence; addiction; adrenergic system; CRF; heroin self administration; opioid induced hyperalgesia

Indexed keywords

CLONIDINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DIAMORPHINE; MPZP; PRAZOSIN; PROPRANOLOL; UNCLASSIFIED DRUG; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; N,N-BIS(2-METHOXYETHYL)-3-(4-METHOXY-2-METHYLPHENYL)-2,5-DIMETHYL-PYRAZOLO(1,5-A)PYRIMIDIN-7-AMINE; NARCOTIC AGENT; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG SELF ADMINISTRATION; HEROIN DEPENDENCE; HYPERALGESIA; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; WITHDRAWAL SYNDROME; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SEEKING BEHAVIOR; METABOLISM;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; CLONIDINE; DRUG-SEEKING BEHAVIOR; HEROIN; HEROIN DEPENDENCE; HYPERALGESIA; NARCOTICS; PRAZOSIN; PROPRANOLOL; PYRIMIDINES; RATS; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SELF ADMINISTRATION;

EID: 84922855851     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/adb.12120     Document Type: Article

References (65)

1. Ahmed SH, Walker JR, Koob GF, (2000) Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology 22: 413-421.
2. Ahmed SH, Lenoir M, Guillem K, (2013) Neurobiology of addiction versus drug use driven by lack of choice. Curr Opin Neurobiol 23: 581-587.
3. Angst MS, Clark JD, (2006) Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104: 570-587.
4. Aston-Jones G, Delfs JM, Druhan J, Zhu Y, (1999) The bed nucleus of the stria terminalis. A target site for noradrenergic actions in opiate withdrawal. Ann NY Acad Sci 877: 486-498.
5. Azar MR, Jones BC, Schulteis G, (2003) Conditioned place aversion is a highly sensitive index of acute opioid dependence and withdrawal. Psychopharmacol (Berl) 170: 42-50.
6. Blaudszun G, Lysakowski C, Elia N, Tramer MR, (2012) Effect of perioperative systemic alpha2 agonists on postoperative morphine consumption and pain intensity: systematic review and meta-analysis of randomized controlled trials. Anesthesiology 116: 1312-1322.
7. Bujalska M, Arazna M, Makulska-Nowak H, Gumulka SW, (2008) Alpha(1) and alpha(2)-adrenoreceptor antagonists in streptozotocin- and vincristine-induced hyperalgesia. Pharmacol Rep 60: 499-507.
8. Celerier E, Laulin JP, Corcuff JB, Le Moal M, Simonnet G, (2001) Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J Neurosci 21: 4074-4080.
9. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL, (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63.
10. Chen HS, Qu F, He X, Wang Y, Wen WW, (2010) Chemical or surgical sympathectomy prevents mechanical hyperalgesia induced by intraplantar injection of bee venom in rats. Brain Res 1353: 86-93.
11. Chen SA, O'Dell LE, Hoefer ME, Greenwell TN, Zorrilla EP, Koob GF, (2006) Unlimited access to heroin self-administration: independent motivational markers of opiate dependence. Neuropsychopharmacology 31: 2692-2707.
12. Chu LF, Cun T, Ngai LK, Kim JE, Zamora AK, Young CA, Angst MS, Clark DJ, (2012) Modulation of remifentanil-induced postinfusion hyperalgesia by the beta-blocker propranolol in humans. Pain 153: 974-981.
13. Compton P, Charuvastra VC, Ling W, (2001) Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend 63: 139-146.
14. Conway EL, Jarrott B, (1980) Clonidine distribution in the rat: temporal relationship between tissue levels and blood pressure response. Br J Pharmacol 71: 473-478.
15. Davoody L, Quiton RL, Lucas JM, Ji Y, Keller A, Masri R, (2011) Conditioned place preference reveals tonic pain in an animal model of central pain. J Pain 12: 868-874.
16. Delaney AJ, Crane JW, Sah P, (2007) Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron 56: 880-892.
17. Edwards S, Koob GF, (2010) Neurobiology of dysregulated motivational systems in drug addiction. Future Neurol 5: 393-401.
18. Edwards S, Koob GF, (2013) Escalation of drug self-administration as a hallmark of persistent addiction liability. Behav Pharmacol 24: 356-362.
19. Edwards S, Graham DL, Whisler KN, Self DW, (2009) Phosphorylation of GluR1, ERK, and CREB during spontaneous withdrawal from chronic heroin self-administration. Synapse 63: 224-235.
20. Edwards S, Vendruscolo LF, Schlosburg JE, Misra KK, Wee S, Park PE, Schulteis G, Koob GF, (2012) Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF(1) receptor antagonism. Neuropharmacology 62: 1142-1151.
21. Egli M, Koob GF, Edwards S, (2012) Alcohol dependence as a chronic pain disorder. Neurosci Biobehav Rev 36: 2179-2192.
22. Eisenach JC, Hood DD, Curry R, (1998) Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers. Anesth Analg 87: 591-596.
23. Fields HL, (2011) The doctor's dilemma: opiate analgesics and chronic pain. Neuron 69: 591-594.
24. Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS, (2008) What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med 9: 444-459.
25. Greenwell TN, Funk CK, Cottone P, Richardson HN, Chen SA, Rice KC, Zorrilla EP, Koob GF, (2009) Corticotropin-releasing factor-1 receptor antagonists decrease heroin self-administration in long- but not short-access rats. Addict Biol 14: 130-143.
26. Harris AC, Gewirtz JC, (2004) Elevated startle during withdrawal from acute morphine: a model of opiate withdrawal and anxiety. Psychopharmacology (Berl) 171: 140-147.
27. He Y, Tian X, Hu X, Porreca F, Wang ZJ, (2012) Negative reinforcement reveals non-evoked ongoing pain in mice with tissue or nerve injury. J Pain 13: 598-607.
28. Heinrichs SC, Menzaghi F, Schulteis G, Koob GF, Stinus L, (1995) Suppression of corticotropin-releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 6: 74-80.
29. Ji G, Neugebauer V, (2007) Differential effects of CRF1 and CRF2 receptor antagonists on pain-related sensitization of neurons in the central nucleus of the amygdala. J Neurophysiol 97: 3893-3904.
30. Ji G, Fu Y, Ruppert KA, Neugebauer V, (2007) Pain-related anxiety-like behavior requires CRF1 receptors in the amygdala. Mol Pain 3: 13.
31. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH, (2010) The prevalence of chronic pain in United States adults: results of an internet-based survey. J Pain 11: 1230-1239.
32. Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF, (2006) Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 26: 5894-5900.
33. Kim SK, Min BI, Kim JH, Hwang BG, Yoo GY, Park DS, Na HS, (2005) Effects of alpha1- and alpha2-adrenoreceptor antagonists on cold allodynia in a rat tail model of neuropathic pain. Brain Res 1039: 207-210.
34. King T, Vera-Portocarrero L, Gutierrez T, Vanderah TW, Dussor G, Lai J, Fields HL, Porreca F, (2009) Unmasking the tonic-aversive state in neuropathic pain. Nat Neurosci 12: 1364-1366.
35. Koob GF, (1999) Corticotropin-releasing factor, norepinephrine, and stress. Biol Psychiatry 46: 1167-1180.
36. Koob GF, (2008) A role for brain stress systems in addiction. Neuron 59: 11-34.
37. Koob GF, Le Moal M, (2008) Addiction and the brain antireward system. Annu Rev Psychol 59: 29-53.
38. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, O'Dell LE, Parsons LH, Sanna PP, (2004) Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev 27: 739-749.
39. Laulin JP, Larcher A, Celerier E, Le Moal M, Simonnet G, (1998) Long-lasting increased pain sensitivity in rat following exposure to heroin for the first time. Eur J Neurosci 10: 782-785.
40. Lenoir M, Ahmed SH, (2008) Supply of a nondrug substitute reduces escalated heroin consumption. Neuropsychopharmacology 33: 2272-2282.
41. Liang DY, Liao G, Wang J, Usuka J, Guo Y, Peltz G, Clark JD, (2006) A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 104: 1054-1062.
42. Liang DY, Shi X, Li X, Li J, Clark JD, (2007) The beta2 adrenergic receptor regulates morphine tolerance and physical dependence. Behav Brain Res 181: 118-126.
43. Liu J, Schulteis G, (2004) Brain reward deficits accompany naloxone-precipitated withdrawal from acute opioid dependence. Pharmacol Biochem Behav 79: 101-108.
44. Maldonado R, (1997) Participation of noradrenergic pathways in the expression of opiate withdrawal: biochemical and pharmacological evidence. Neurosci Biobehav Rev 21: 91-104.
45. Martin TJ, Eisenach JC, (2001) Pharmacology of opioid and nonopioid analgesics in chronic pain states. J Pharmacol Exp Ther 299: 811-817.
46. Martin TJ, Kim SA, Buechler NL, Porreca F, Eisenach JC, (2007) Opioid self-administration in the nerve-injured rat: relevance of antiallodynic effects to drug consumption and effects of intrathecal analgesics. Anesthesiology 106: 312-322.
47. McNally GP, Akil H, (2002) Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. Neuroscience 112: 605-617.
48. Nackley AG, Tan KS, Fecho K, Flood P, Diatchenko L, Maixner W, (2007) Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors. Pain 128: 199-208.
49. Park PE, Vendruscolo LF, Schlosburg JE, Edwards S, Schulteis G, Koob GF, (2013) Corticotropin-releasing factor (CRF) and alpha 2 adrenergic receptors mediate heroin withdrawal-potentiated startle in rats. Int J Neuropsychopharmacol 16: 1867-1875.
50. Richardson HN, Zhao Y, Fekete EM, Funk CK, Wirsching P, Janda KD, Zorrilla EP, Koob GF, (2008) MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol Biochem Behav 88: 497-510.
51. Ririe DG, Eisenach JC, (2006) Age-dependent responses to nerve injury-induced mechanical allodynia. Anesthesiology 104: 344-350.
52. Rothwell PE, Thomas MJ, Gewirtz JC, (2009) Distinct profiles of anxiety and dysphoria during spontaneous withdrawal from acute morphine exposure. Neuropsychopharmacology 34: 2285-2295.
53. Safieh-Garabedian B, Poole S, Haddad JJ, Massaad CA, Jabbur SJ, Saade NE, (2002) The role of the sympathetic efferents in endotoxin-induced localized inflammatory hyperalgesia and cytokine upregulation. Neuropharmacology 42: 864-872.
54. Schulteis G, Koob GF, (1996) Reinforcement processes in opiate addiction: a homeostatic model. Neurochem Res 21: 1437-1454.
55. Schulteis G, Heyser CJ, Koob GF, (1999) Differential expression of response-disruptive and somatic indices of opiate withdrawal during the initiation and development of opiate dependence. Behav Pharmacol 10: 235-242.
56. Self DW, Nestler EJ, (1998) Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend 51: 49-60.
57. Shaham Y, Highfield D, Delfs J, Leung S, Stewart J, (2000) Clonidine blocks stress-induced reinstatement of heroin seeking in rats: an effect independent of locus coeruleus noradrenergic neurons. Eur J Neurosci 12: 292-302.
58. Shurman J, Koob GF, Gutstein HB, (2010) Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med 11: 1092-1098.
59. Simonnet G, Rivat C, (2003) Opioid-induced hyperalgesia: abnormal or normal pain? Neuroreport 14: 1-7.
60. Smith RJ, Aston-Jones G, (2008) Noradrenergic transmission in the extended amygdala: role in increased drug-seeking and relapse during protracted drug abstinence. Brain Struct Funct 213: 43-61.
61. Stowe GN, Vendruscolo LF, Edwards S, Schlosburg JE, Misra KK, Schulteis G, Mayorov AV, Zakhari JS, Koob GF, Janda KD, (2011) A vaccine strategy that induces protective immunity against heroin. J Med Chem 54: 5195-5204.
62. Tierney C, Nadaud D, Koenig-Berard E, Stinus L, (1988) Effects of two alpha 2 agonists, rilmenidine and clonidine, on the morphine withdrawal syndrome and their potential addictive properties in rats. Am J Cardiol 61: 35D-38D.
63. Vendruscolo LF, Schlosburg JE, Misra KK, Chen SA, Greenwell TN, Koob GF, (2011) Escalation patterns of varying periods of heroin access. Pharmacol Biochem Behav 98: 570-574.
64. Weiss F, Ciccocioppo R, Parsons LH, Katner S, Liu X, Zorrilla EP, Valdez GR, Ben-Shahar O, Angeletti S, Richter RR, (2001) Compulsive drug-seeking behavior and relapse. Neuroadaptation, stress, and conditioning factors. Ann NY Acad Sci 937: 1-26.
65. Zhang Z, Schulteis G, (2008) Withdrawal from acute morphine dependence is accompanied by increased anxiety-like behavior in the elevated plus maze. Pharmacol Biochem Behav 89: 392-403.